---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-080473"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:08:38.127542+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rezolute appoints Sunil Karnawat as CCO; grants 275K inducement options

## Summary
- Sunil Karnawat appointed Chief Commercial Officer effective Aug 18, 2025; brings 25+ years experience including four ultra-rare disease launches at Ultragenyx.
- Employment agreement: base salary $475K, annual target bonus 40%, signing bonus $65K, plus 270K stock options and 25K RSUs vesting over time.
- Inducement grant of 275K stock options at $6.55/share (closing price Aug 18); vesting: 25% on first anniversary, then 36 monthly installments, accelerated upon change of control.
- Karnawat will lead launch strategy and global market readiness for ersodetug, a Phase 3 therapy for congenital and tumor hyperinsulinism.

## SEC filing metadata
- accession: 0001104659-25-080473
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/0001104659-25-080473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/tm2523938d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-080473
- JSON: https://secwatch.observer/filing/0001104659-25-080473.json
- Plain text: https://secwatch.observer/filing/0001104659-25-080473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.